A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment

Ibogaine is a naturally occurring indole alkaloid from Tabernanthe iboga that has drawn attention for its purported capacity to alleviate opioid withdrawal and reduce craving. Camlin and colleagues frame the study against rising opioid-related harms and a growing, albeit incomplete, empirical literature suggesting ibogaine and its metabolite noribogaine may modulate neural circuits implicated in addiction. They note safety concerns and a stalled formal research programme, which have contributed to an informal ‘‘underground’’ treatment network and a need for deeper qualitative understanding of the subjective ibogaine experience in people seeking opioid detoxification. This study set out to characterise the lived, subjective experiences of individuals who underwent ibogaine treatment for opioid dependence, using a phenomenological approach to identify commonalities and emergent themes. The investigators intended to explore how the ibogaine experience affects withdrawal, craving, perceptual phenomena, bodily effects, and shifts in outlook or self-perception, with the aim of informing future treatment protocols and research directions.

The study used a phenomenological, emergent-design qualitative method based on in-depth, semi-structured interviews. Ten US citizens who received ibogaine treatment at Crossroads Treatment Center in Rosarito, Mexico (facility since relocated) comprised the purposive sample. Interviews were conducted face-to-face three days after treatment at the clinic, except one interview performed in San Diego three months post-treatment. The sample included seven men and three women, ages 21–48 (mean 28.8 years), educational attainment from 11th grade to a master’s degree, and a racial/ethnic composition of seven Caucasian, two Hispanic, and one African American participant. The authors note the sample size of 10 was smaller than typical qualitative recommendations but was intentional to allow depth of enquiry. Interview questions were developed by the study team and drew in part on prior instruments; transcribed interviews were analysed using the constant comparative method to identify themes and emergent categories. Trustworthiness was addressed through a literature review, frequent debriefing among the primary researcher, co-authors and colleagues, and steps to increase transparency in interpretation. Ethical oversight included IRB approval at Alliant International University, informed consent with permission to audiotape, and adherence to APA ethical principles; the primary researcher conducted all interviews and reported no prior affiliation with the treatment centre in a clinical capacity.

Analysis produced 13 themes grouped into four main categories: (I) neurological and physical effects, (II) auditory and visual phenomena, (III) alleviation of withdrawal and cravings, and (IV) changed perspectives. A separate theme of traumatic histories in participants' backgrounds also emerged: 90% reported using substances to cope with traumatic experiences. Category I (neurological and physical effects) included reports of subjective localized brain sensations, and pervasive physical drain described by 80% of participants. Five of 10 participants reported impaired psychomotor coordination, dizziness and/or vomiting; examples include participants saying they felt ‘‘nauseous’’ and ‘‘threw up,’’ felt like they were ‘‘spinning around the room,’’ or that standing made them feel ‘‘90 years old.’’ Participants used terms such as feeling ‘‘heavy,’’ ‘‘sore,’’ and ‘‘wiped out.’’ Category II (auditory and visual phenomena) comprised six themes. Eighty percent described a buzzing or vibration sound at onset (e.g. repeated ‘‘bzzzzzzz’’). Seventy percent reported entering distinct settings or environments—dream-like scenes that varied widely across individuals, from womb-like or ancestral settings to outer space or hellish institutions. Sixty percent reported cyclical or organisational imagery (for instance repetitive motifs or ‘‘filing cabinet’’ metaphors), and 80% experienced a mixture of dark/scary and joyful/peaceful imagery. Difficulty articulating details was prominent: 90% said the experience was hard to describe, reporting many rapid, vivid visions that were difficult to recall in full. Category III (alleviation of withdrawal and cravings) was strongly concordant across participants: 100% endorsed nearly immediate and sustained attenuation of opioid withdrawal symptoms during and after ibogaine, and all participants reported minimal to no cravings in the period following treatment. Illustrative remarks include one participant noting ‘‘I’m not sick’’ despite extended abstinence and another reporting that cravings that previously lasted 30–40 minutes were dissipated within a minute or two after ibogaine. Category IV (changed perspectives) covered shifts in self-regard and worldview. All participants reported increased self-acceptance and decreased self-critical thinking after the experience, with statements such as ‘‘[ibogaine] gave me more self-love.’’ Seventy percent reported a more spiritual outlook, described as greater connectedness and meaning. Finally, all participants expressed a conviction that ibogaine could be effective in helping others with substance problems. Follow-up was limited: attempts were made within six months but only two participants responded; both indicated they were doing well and did not dispute the study’s thematic findings, and both emphasised the value of continuing care.

Camlin and colleagues interpret their findings as largely consistent with earlier qualitative work on ibogaine while also noting some divergences. They argue the study reinforces recurrent features of the ibogaine experience—intense visionary phenomena, profound bodily fatigue, and rapid relief from opioid withdrawal and craving—yet did not replicate reports from other studies of distinct subjective ‘‘phases’’ (visionary, evaluation, integration), suggesting such phases may be more apparent to providers than to patients themselves. The authors highlight that a subjective sense of localized brain activation emerged in their sample and appears novel relative to prior reports. The investigators situate the visionary content within prior work that likens ibogaine visions to waking dreams, citing animal EEG evidence of REM-like rhythms as supporting biological plausibility. They propose that if psychotherapy is incorporated into an ibogaine treatment model, techniques oriented to dream work or Jungian analysis might aid integration. The consistent, often immediate reduction in withdrawal and craving is emphasised as clinically relevant because these factors drive continued opioid use; the authors suggest ibogaine’s attenuation of craving could make it a useful adjunct to behavioural therapies. Authors acknowledge several limitations: the small, convenience sample (n = 10) limits generalisability; participants were recruited from a single treatment facility that was founded by two co-authors, introducing potential selection bias despite the authors' statement that those co-authors did not participate in theme identification; voluntary participation may have favoured individuals with positive experiences; participant demographics were relatively homogeneous (mostly Caucasian men with Christian backgrounds); and variable treatment protocols across clinics constrain transferability. The study team also disclose a potential pro-ibogaine bias among some authors, and note steps taken to enhance credibility and to include more sceptical co-authors. In terms of implications, the authors call for standardised ibogaine treatment protocols and point to MDMA-assisted psychotherapy as a possible procedural model. They recommend further research into incorporating continuing care components—cognitive-behavioural therapy to consolidate increased self-acceptance, journaling or audio recording to improve recall of visions for integration, and exploration of dream-analysis or logotherapy techniques. Overall, the authors contend their findings support continued investigation of ibogaine’s potential to attenuate opioid withdrawal and craving and to produce subjectively meaningful experiences that may aid recovery.